An investigational antifibrotic and anti-inflammatory drug could help treat a common complication of diabetes.
Advances in kidney care have not led to successful efforts to improve therapy for patients with Type 1 diabetes, according to a study published in the Journal of the American Society of Nephrology.
Amicus Therapeutics received good results from its mid-stage trial of a drug for a rare, genetic disorder, the drug maker said Wednesday.